Science News
from research organizations

T cell revival through PD-1: Clues for cancer immunotherapy

PD-1-responsive cells could be targets for drug combinations

Date:
August 2, 2016
Source:
Emory Health Sciences
Summary:
Scientists show which molecular features distinguish the subset of exhausted T cells that can be re-energized, when mice with chronic viral infections are treated with PD-1-blocking agents. Useful information for optimizing cancer immunotherapy and combinations with other drugs.
Share:
FULL STORY

Spleen of LCMV-infected mouse. The population of PD-1-responsive T cells is CD8+ and TCF1+ and thus appears as yellow.
Credit: From Im et al. Nature (2016)

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs.

Scientists from Emory Vaccine Center have now shown what molecular features distinguish the subset of T cells that wake up when re-energized by PD-1-blocking agents.

The researchers expect that their findings will be valuable for optimizing treatment with PD-1-targeting drugs. The experiments were performed in mice with chronic viral infections, the system in which T cell exhaustion and PD-1's immune-braking function were first discovered.

The results are published in Nature.

PD-1-blocking agents such as nivolumab, pembrolizumab and atezolizumab are part of a class of drugs known as checkpoint inhibitors, and many cancer researchers are now trying to figure out how to enhance their activity by combining them with other types of drugs.

"If we know more about the markers on the T cells that expand after PD-1's inhibition is removed, that could facilitate the rational design of combination therapies," says senior author Rafi Ahmed, PhD, director of Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar.

The first author of the Nature paper is postdoctoral fellow Sejin Im, PhD. Collaborators from NIAID (National Institute of Allergy and Infectious Diseases), University of Iowa, Harvard Medical School, Dana Farber Cancer Institute and University of São Paolo, Brazil contributed to the paper.

More than a decade ago, Ahmed and colleagues had shown that the immune systems of mice with chronic viral infections were full of inactive, or "exhausted" antiviral T cells. These cells displayed high levels of PD-1, and antiviral activity could be revived if PD-1's interactions with its counterpart on other cells (PD-L1) were blocked.

In the current paper, the authors demonstrate that the exhausted antiviral T cells can be divided into two groups. One group undergoes a proliferative burst when virus-infected mice are given PD-1-blocking antibodies, and the other group lacks the capacity to proliferate.

Even before PD-1-blocking antibodies were introduced, the expandable group of virus-specific T cells was dividing at a slow rate. These cells were only in the T cell zones of lymphoid organs (lymph nodes and spleen), not circulating throughout the body. After PD-1 is blocked, these cells divide and differentiate into effector-like cells that migrate to infected tissues.

"If you imagine chronic viral infection -- or cancer -- as a war, the expandable T cells are not in the intense part of the battle," Ahmed says. "But they are somewhat engaged. It's like they're waiting in a shelter, ready to respond."

The researchers also showed that a gene called TCF1 was important for the generation and maintenance of the PD-1-responsive T cells in mice. Inside and outside, the PD-1-responsive cells had molecular characteristics that resembled memory T cells or stem-like cells, while the non-responsive T cells were more terminally differentiated.

The authors catalogued several co-stimulatory molecules and receptors present on the surfaces of the PD-1-responsive T cells, which possibly could be targets for drugs.

In collaboration with researchers at Winship Cancer Institute of Emory University, Ahmed's laboratory is looking for immune cells with similar characteristics in cancer patients. It is possible that this group of revivable T cells may be found in contact with the tumor, or perhaps more likely, in lymph nodes nearby, Ahmed says.


Story Source:

Materials provided by Emory Health Sciences. Note: Content may be edited for style and length.


Journal Reference:

  1. Se Jin Im, Masao Hashimoto, Michael Y. Gerner, Junghwa Lee, Haydn T. Kissick, Matheus C. Burger, Qiang Shan, J. Scott Hale, Judong Lee, Tahseen H. Nasti, Arlene H. Sharpe, Gordon J. Freeman, Ronald N. Germain, Helder I. Nakaya, Hai-Hui Xue, Rafi Ahmed. Defining CD8 T cells that provide the proliferative burst after PD-1 therapy. Nature, 2016; DOI: 10.1038/nature19330

Cite This Page:

Emory Health Sciences. "T cell revival through PD-1: Clues for cancer immunotherapy: PD-1-responsive cells could be targets for drug combinations." ScienceDaily. ScienceDaily, 2 August 2016. <www.sciencedaily.com/releases/2016/08/160802125207.htm>.
Emory Health Sciences. (2016, August 2). T cell revival through PD-1: Clues for cancer immunotherapy: PD-1-responsive cells could be targets for drug combinations. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2016/08/160802125207.htm
Emory Health Sciences. "T cell revival through PD-1: Clues for cancer immunotherapy: PD-1-responsive cells could be targets for drug combinations." ScienceDaily. www.sciencedaily.com/releases/2016/08/160802125207.htm (accessed May 23, 2017).

RELATED STORIES